Australia - English - Department of Health (Therapeutic Goods Administration)

sunpab health products pty ltd - cysteine hydrochloride,lycopersicon esculentum,rosa rugosa -

Australia - English - Department of Health (Therapeutic Goods Administration)

kissun pharmaceuticals pty ltd - cysteine hydrochloride, quantity: 60 mg; rosa rugosa, quantity: 5 mg; lycopersicon esculentum, quantity: 80 mg (equivalent: lycopersicon esculentum, qty 800 mg; equivalent: phytoene and phytofluene, qty 0.046 mg; equivalent: steroidal alkaloids calculated as solanine, qty 0.046 mg) - tablet, uncoated - excipient ingredients: isomalt; magnesium stearate; microcrystalline cellulose - traditionally used in european herbal medicine to helps enhance/improve/promote/increase skin firmness ; traditionally used in european herbal medicine to maintain/support skin repair/healing/regeneration

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is the nonproprietary name for the n-acetyl derivative of the naturally occurring amino acid, l-cysteine. chemically, it is n-acetyl-l-cysteine. the compound is a white crystalline powder which melts in the range of 104° to 110°c and has a very slight odor. the structural formula of acetylcysteine is: c5 h9 no3 s                                                                                                      m.w.=163.19 acetylcysteine solution, usp is supplied as a sterile unpreserved solution (not for injection) in vials containing a 10% (100 mg/ml) or 20% (200 mg/ml) solution of acetylcysteine as the sodium salt. the inactive ingredients are edetate disodium, sodium hydroxide and sterile water for injection, usp. the ph of the solution ranges from 6.0 to 7.5. it is administered by inhalation or direct instillation for mucolysis, or orally for acetaminophen overdosage.

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion. there are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.

United States - English - NLM (National Library of Medicine)

american regent, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as po

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine solution, usp is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine solution, usp administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate trea

United States - English - NLM (National Library of Medicine)

hospira, inc. - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 100 mg in 1 ml - acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease     (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) acute bronchopulmonary disease     (pneumonia, bronchitis, tracheobronchitis) pulmonary complications of cystic fibrosis tracheostomy care pulmonary complications associated with surgery use during anesthesia post-traumatic chest conditions atelectasis due to mucous obstruction diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) acetylcysteine is contraindicated in those patients who are sensitive to it. acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. it is essential to initiate treatment as soon as

United States - English - NLM (National Library of Medicine)

eugia us llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 6 g in 30 ml - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1)] . risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects

United States - English - NLM (National Library of Medicine)

padagis us llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (rsi). acetylcysteine injection is contraindicated in patients with a previous hypersensitivity reaction to acetylcysteine [see warnings and precautions (5.1) ]. risk summary limited published case reports and case series of pregnant women exposed to acetylcysteine during various trimesters are not sufficient to inform any drug associated risk. delaying treatment of acetaminophen overdose may increase the risk of maternal or fetal morbidity and mortality [see clinical considerations ]. reproduction studies in rats and rabbits following oral administration of acetylcysteine during the period of organogenesis at doses similar to the total intravenous dose (based on the body surface area) did not cause any adverse effects to the fetus. the estimated background risk of major birth defects and mi

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - acetylcysteine (unii: wyq7n0bpyc) (acetylcysteine - unii:wyq7n0bpyc) - acetylcysteine 200 mg in 1 ml - acetylcysteine injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. overdose incidences are divided into two types; acute ingestion or repeated supratherapeutic ingestion (rsi). [see dosage and administration ( 2 ) and acetaminophen assays – interpretation and methodology -(acute or repeated supratherapeutic ingestion) ( 1.1 , 1.2 )] . on admission for suspected acetaminophen overdose, a serum blood sample should be drawn at least 4 hours after ingestion to determine the acetaminophen level and will serve as a basis for determining the need for treatment with acetylcysteine. if the patient presents after 4 hours post-ingestion, the serum acetaminophen sample should be determined immediately. acetylcysteine injection should be administered within 8 hours from acetaminophen ingestion for maximal protection against hepatic injury for patients whose serum acetaminop